Application of microRNA-21a-5p in preparation of medicine for preventing and / or treating transient ischemic attack
By developing drugs that utilize microRNA-21a-5p, promoting angiogenesis and brain microvascular endothelial cell functions, the problem of lack of effective treatment for brain tissue damage after transient ischemia attacks in the prior art has been solved, and significant brain injury repair has been achieved Effect.
Patent Information
- Application Number
- CN202410854759.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective means of treating brain tissue damage after transient ischemia attacks, and the basic scientific basis for the application of microRNA in this field is insufficient.
Developing drugs that utilize microRNA-21a-5p, through its nucleotide sequence 3'-AGUUGUAGUCAGACUAUUCGAU-5', promote angiogenesis, increase microvascular density and number of neovascularization, upregulate the expression of pro-angiogenic factors, and enhance the brain microvascular endothelial cells. Proliferation, migration and angiogenesis capacity.
It significantly improves brain tissue damage and improves the effect of brain injury repair, providing a new potential strategy for the treatment of transient ischemia attacks.
Smart Images

Figure CN118903180A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to the application of microRNA-21a-5p in preparing a drug for preventing and / or treating transient ischemic attack. Background Art
[0002] Transient ischemic attack (TIA) refers to transient neurological dysfunction caused by focal ischemia of the brain, spinal cord or retina without acute cerebral infarction. Demographic research data show that in Europe, the age-standardized prevalence of TIA is 28-59 / 100,000 / year; in my country, the age-standardized prevalence of TIA is 2.27%, but the standardized treatment rate is only 4.07%. Studies in recent years have found that TIA is an important warning sign of stroke and increases the risk of long-term functional disability or death. In addition, TIA may also cause long-term adverse prognostic events such as cognitive decline, emotional disorders, and brain atrophy, which seriously affect the patient's quality of life and social function. Therefore, full attention should be paid to the prevention and treatment of TIA.
[0003] According to the latest definition, the absence of ischemic high signal in diffusion-weighted imaging (DWI) sequence in magnetic resonance imaging (MRI) is often used as a condition for diagnosing TIA in clinical practice, but this does not mean that the brain tissue structure in the responsible area is completely normal. The increase in brain atrophy rate after TIA reflects persistent brain tissue damage at the subclinical level. Through resting-state functional magnetic resonance imaging, abnormal connections of local or widespread brain networks have also been found in TIA patients. A few previous animal studies have also confirmed that after transient cerebral ischemia, although there is no persistent neurological deficit and detectable imaging abnormalities, histopathological examinations can reveal selective neuronal necrosis and apoptosis, suggesting that TIA may cause irreversible brain tissue damage. However, the current clinical focus on TIA is mainly on secondary prevention, and there is still a lack of effective treatment for the repair of brain tissue after damage. Therefore, it is urgent to develop new targets to treat TIA.
[0004] MicroRNA (miRNA) is a class of endogenous non-coding single-stranded RNA molecules with a length of about 18 to 25 nucleotides, which play a post-transcriptional regulatory role in gene expression. In recent years, increasing evidence has shown that many miRNAs promote neurological recovery after ischemic stroke by regulating genes involved in processes such as neuroprotection, neurogenesis, and angiogenesis. In view of this, regulating the expression level of miRNA through exogenous intervention may be a potential strategy for the treatment of ischemic stroke. Compared with traditional drug therapy, the development of specific miRNA analogs or antisense oligonucleotides to treat TIA has the following advantages:
[0005] First, it is easier to manufacture than other drugs, and it can reduce the blindness of drug development and the development process is faster;
[0006] Secondly, since each miRNA usually targets multiple mRNAs, it can play a regulatory role in multiple processes of disease treatment and enhance the recovery of TIA patients;
[0007] Third, after administration, it can directly enter cells and exert its effects;
[0008] Fourth, endogenous miRNAs are usually produced rapidly and degraded slowly, persisting for a long time in human cells, increasing the feasibility of exogenous drug intervention.
[0009] Therefore, targeted regulation of miRNA will have a very broad market prospect in TIA patients.
[0010] MicroRNA-21a-5p (miR-21a-5p) is located on chromosome 17q23.2 and was confirmed by Lagos-Quintana et al. in 2001. Subsequent studies have found that miR-21a-5p can promote endothelial cell activation and proliferation, as well as tumor cell proliferation, migration and invasion, and inhibit cell apoptosis and inflammatory response. Although the literature has reported a variety of physiological and pathological functions of miR-21a-5p, its role in the prevention and treatment of TIA still lacks experimental basic scientific evidence. Summary of the invention
[0011] In order to overcome the deficiencies of the above-mentioned prior art, the present invention provides the use of microRNA-21a-5p in the preparation of a drug for preventing and / or treating transient ischemic attack, which can promote angiogenesis, increase the density of microvessels and the number of new blood vessels, up-regulate the expression of angiogenesis-promoting factors, and enhance the proliferation, migration and angiogenesis ability of brain microvascular endothelial cells.
[0012] In order to achieve the above purpose, this application adopts the following technical solutions:
[0013] The present invention provides use of microRNA-21a-5p in preparing a drug for preventing and / or treating transient ischemic attack. The nucleotide sequence of microRNA-21a-5p is shown in SEQ ID NO: 1, which is 3'-AGUUGUAGUCAGACUAUUCGAU-5'.
[0014] In the above technical solution, transient ischemic attack refers to a transient ischemic attack caused by middle cerebral artery occlusion.
[0015] In the above technical scheme, microRNA-21a-5p can promote angiogenesis.
[0016] In the above technical solution, promoting angiogenesis includes increasing the density of microvessels and the number of new blood vessels, and upregulating the expression of angiogenesis-promoting factors; the angiogenesis-promoting factors include VEGF, Ang-1 and Ang-2.
[0017] In the above technical solution, promoting angiogenesis also includes enhancing the proliferation, migration and angiogenesis ability of brain microvascular endothelial cells.
[0018] The beneficial effects of the present invention are as follows: the present invention provides a new use of miR-21a-5p in the preparation of drugs for preventing and / or treating TIA, which can improve brain tissue damage and play a role in promoting angiogenesis. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The results of angiogenesis detection in mouse brain tissue;
[0020] Figure 2 These are the results of angiogenesis test of brain microvascular endothelial cells. DETAILED DESCRIPTION
[0021] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. The present invention can be implemented in many different forms and should not be construed as being limited to the embodiments set forth herein. On the contrary, these embodiments are provided so that this disclosure will be thorough and complete, and the concept of the present invention will be fully conveyed to those skilled in the art, and the present invention will only be limited by the claims.
[0022] The invention discloses the use of miR-21a-5p in preparing a medicine for preventing and / or treating TIA, and conducts animal and cell experiments respectively.
[0023] 1. Animal Experiments
[0024] Animal experiments were conducted on C57 wild-type mice. The middle cerebral artery was occluded for 8 minutes by suture embolism to simulate human TIA. The mice were randomly divided into the following 4 groups: normal control group (Sham), TIA model group (TIA), negative control group (TIA+NCagomir), and miR-21a-5p analog group (TIA+miR-21a-5pagomir). The miR-21a-5p analog was diluted to 0.5nmol / μl with normal saline and injected into the lateral ventricle 24 hours before TIA modeling. Each mouse in the miR-21a-5p analog group was given 1nmol; the mice in the negative control group were given the same dose of negative control analog by intracerebroventricular injection. On the third day after TIA modeling, the total protein of the brain tissue of each group of mice was extracted, and the expression level of angiogenic factors was detected by western blotting. On the 10th day after TIA modeling, brain tissues of mice in each group were fixed in paraformaldehyde solution and frozen sections were made. Immunofluorescence staining was used to detect the density of microvessels and the number of new blood vessels to show the role of miR-21a-5p in the repair of brain damage after TIA.
[0025] Figure 1 Figure 2 is the result of angiogenesis detection in mouse brain tissue. 24 hours before TIA modeling, C57 male mice were injected with miR-21a-5p analogs or negative control analogs into the lateral ventricle, where A is the microvessel density detection of mouse brain tissue (scale is 100μm), and the results show that compared with the negative control group, the microvessel density in the brain tissue of mice in the miR-21a-5p analog group was significantly increased; B is the number of new blood vessels in mouse brain tissue (scale is 50μm; scale of local magnification is 15μm), and the results show that compared with the negative control group, the number of new blood vessels in the miR-21a-5p analog group was significantly increased; C is the protein expression level of VEGF and Ang-1 in mouse brain tissue, and the results show that compared with the negative control group, the expression level of angiogenesis-promoting factors in brain tissue was significantly increased after administration of miR-21a-5p analogs. (*P<0.05, **P<0.01, ****P<0.0001, compared with the Sham group; #P<0.05, ##P<0.01, ###P<0.001, compared with the TIA+NC agomir group)
[0026] The results of animal experiments showed that compared with the model group without medication, the administration of miR-21a-5p analogs could significantly increase the microvessel density and the number of new blood vessels in the brain tissue of the model group mice, upregulate the expression of angiogenesis factors, and improve brain tissue damage.
[0027] 2. Cell Experiment
[0028] In the cell experiment, brain microvascular endothelial cells were used as the research object. An in vitro TIA cell model was constructed by combining glucose-oxygen deprivation and reoxygenation to explore the effect of miR-21a-5p on in vitro TIA angiogenesis. The cells were randomly divided into the following 4 groups: normal control group (Control), TIA model group (OGD / R), negative control group (OGD / R+NC inhibitor), and miR-21a-5p inhibitor group (OGD / R+miR-21a-5p inhibitor). Among them, the miR-21a-5p inhibitor with a final concentration of 150nM was added to the culture medium of the cells in the miR-21a-5p inhibitor group, and the negative control inhibitor with a final concentration of 150nM was added to the negative control group. 36 hours after administration, the cells in each group were modeled with TIA. 12 hours after TIA modeling, the cells in each group were collected, and the proliferation ability of the cells was detected by immunofluorescence staining, the migration ability of the cells was evaluated by scratch test and Transwell cell migration test, and the angiogenesis ability of the cells was detected by tube formation test. In addition, 12 hours after TIA modeling, the total protein of cells in each group was extracted, and the expression levels of angiogenic factors were detected by western blotting.
[0029] Figure 2 is the result of angiogenesis function test of brain microvascular endothelial cells. 36 hours before the construction of cell TIA model, brain microvascular endothelial cells were treated with miR-21a-5p inhibitor or negative control inhibitor. Among them, AB is the proliferation ability test of brain microvascular endothelial cells (scale is 100μm). The results showed that compared with the negative control group, the proliferation ability of cells in the miR-21a-5p inhibitor group was significantly reduced; CD is the migration ability test of brain microvascular endothelial cells (scale is 100μm). The results showed that compared with the negative control group, the migration ability of cells in the miR-21a-5p inhibitor group was significantly reduced; EF is the angiogenesis ability test of brain microvascular endothelial cells (scale is 200μm). The results showed that compared with the negative control group, the administration of miR-21a-5p inhibitor can significantly reduce the angiogenesis ability of cells; GH is the protein expression level of VEGF, Ang-1 and Ang-2 in brain microvascular endothelial cells. The results showed that compared with the negative control group, the expression level of angiogenesis-promoting factors in the miR-21a-5p inhibitor group was significantly decreased. (**P<0.01, ***P<0.001, ****P<0.0001, compared with the Control group; ##P<0.01, ####P<0.0001, compared with the OGD / R+NC inhibitor group)
[0030] The results of cell experiments showed that compared with the model group, inhibiting the expression level of miR-21a-5p in brain microvascular endothelial cells could significantly reduce the proliferation, migration and angiogenesis ability of cells, and downregulate the expression of angiogenic factors.
[0031] Therefore, miR-21a-5p can promote the repair of brain damage after TIA and has good efficacy and promising value in preparing drugs for preventing and / or treating TIA.
[0032] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. Use of microRNA-21a-5p in the preparation of a drug for preventing and / or treating transient ischemic attack, characterized in that: The nucleotide sequence of microRNA-21a-5p is shown in SEQ ID NO: 1, which is 3'-AGUUGUAGUCAGACUAUUCGAU-5'.
2. The application according to claim 1, characterized in that: A transient ischemic attack is a transient ischemic attack caused by a blockage of the middle cerebral artery.
3. The application according to claim 1, characterized in that: microRNA-21a-5p can promote angiogenesis.
4. The application according to claim 3, characterized in that: Promoting angiogenesis includes increasing the density of microvessels and the number of new blood vessels, and upregulating the expression of angiogenesis-promoting factors; the angiogenesis-promoting factors include VEGF, Ang-1 and Ang-2.
5. The application according to claim 3, characterized in that: Promoting angiogenesis also includes enhancing the proliferation, migration and angiogenesis ability of brain microvascular endothelial cells.
Citation Information
Patent Citations
Method for observing dynamic distribution of tumor cell exosome and exosome internal miRNA in recipient cells
CN108192951A
